Tokyo, Japan

Toru Mizushima

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 2.1

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Kumamoto, JP (2013)
  • Tokyo, JP (2015 - 2017)

Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovations of Toru Mizushima

Introduction

Toru Mizushima is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of respiratory diseases. With a total of five patents to his name, Mizushima's work focuses on developing therapeutic agents that address critical health issues.

Latest Patents

Mizushima's latest patents include an innovative therapeutic agent for treating acute respiratory distress syndrome. This agent features a lecithinized superoxide dismutase as its active ingredient, which is designed to combat oxidative stress in patients. Another significant patent is for an agent aimed at ameliorating chronic obstructive pulmonary disease (COPD). This agent contains mepenzolate bromide, which provides both bronchodilator and anti-inflammatory effects, making it a promising treatment option for individuals suffering from COPD.

Career Highlights

Throughout his career, Mizushima has worked with various organizations, including LTT Bio-pharma Co., Ltd. and Kumamoto University. His experience in these institutions has allowed him to advance his research and develop effective therapeutic solutions.

Collaborations

Mizushima has collaborated with notable colleagues such as Hongxing Liu and Yoshinari Okamoto. These partnerships have contributed to the success of his innovative projects and patents.

Conclusion

Toru Mizushima's contributions to medical innovation, particularly in respiratory treatments, highlight his role as a significant inventor in the field. His patents reflect a commitment to improving patient care and addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…